Dapsone as a Glucocorticoid-Sparing Agent in Maintenance-Phase Pemphigus Vulgaris

Heaphy, Michael R.; Albrecht, Joerg; Werth, Victoria P.

doi:10.1001/archderm.141.6.699

Cited by 34 publications

(23 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Back in 1976, a review of 107 consecutive cases of pemphigus demonstrated dapsone to be a useful adjuvant to systemic corticosteroids [10] . Since then, dapsone's efficacy as a steroid-sparing agent in the treatment of PV has been documented in several reports [11][12][13][14][15][16][17][18][19][20] . However, the current data are mainly based on small retrospective case series and reports.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Dapsone in the Treatment of Pemphigus Vulgaris: A Single-Center Case Study

Baum¹,

Debby²,

Gilboa³

et al. 2016

Dermatology

View full text Add to dashboard Cite

Background: Pemphigus vulgaris (PV) is a chronic autoimmune blistering disease. Most patients require long-term therapy with systemic steroids, and a steroid-sparing agent is usually also utilized. Dapsone is a chemotherapeutic agent with anti-inflammatory properties that is used as a steroid-sparing agent in PV. Objective: The aim of the present study was to evaluate the efficacy of dapsone as an adjuvant therapy in patients with PV. Methods: A retrospective analysis of patients' files was performed. All 26 patients included in the study group were treated with dapsone as an adjuvant to systemic steroids for at least 3 consecutive months and were followed up during their dapsone treatment period. Results: After 3 months of treatment with dapsone, 13 patients were in the consolidation phase, 4 patients demonstrated partial remission on minimal therapy, 7 patients demonstrated complete remission on minimal therapy, and 2 patients were defined as treatment failures. The trend of clinical improvement continued after 6 months of treatment and at the study end point. Conclusion: This retrospective case series, one of the largest reported, indicates that dapsone is efficacious and safe for patients with PV in whom it is well tolerated soon after the initiation of treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Dapsone in the Treatment of Pemphigus Vulgaris: A Single-Center Case Study

Baum¹,

Debby²,

Gilboa³

et al. 2016

Dermatology

View full text Add to dashboard Cite

show abstract

“…Side effects include headache, lethargy, hemolysis, methemoglobinemia, agranulocytosis, leukopenia, peripheral neuropathy, cutaneous eruptions, psychosis, and GI complications. 12 Avoidance of side effects can be achieved by starting at low doses and slowly increasing the dose while obtaining blood tests, particularly a complete blood cell count (CBC) to monitor for anemia. Patients with significant atherosclerotic disease and other conditions in which even mild anemia may not be well tolerated should avoid using dapsone.…”

Section: Corticosteroid-sparing Agents and Their Side Effectsmentioning

confidence: 99%

Minimizing Complications in Autoimmune Blistering Diseases

Clay

Pandya

2011

Dermatologic Clinics

View full text Add to dashboard Cite

“…Recent clinical evidence supports that it can be useful as a glucocorticoid-sparing agent during the maintenance phase of pemphigus (9). A possible mechanism that may account for the effectiveness of this drug seems to be the inhibition of eosinophilic spongiosis observed in pemphigus lesions (10).…”

Section: Discussionmentioning

confidence: 99%

Pemphigus foliaceus induced by radiotherapy and responsive to dapsone

Cianchini

Lembo

Colonna

et al. 2006

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Pemphigus foliaceus induced by ionizing radiation therapy is a rare condition. We describe the case of a 70-year-old female who developed pemphigus foliaceus after X-ray treatment for an adenocarcinoma of the left breast. The eruption started at the portal of irradiation and only subsequently spread to other cutaneous areas. Mucosal membranes were not affected. Skin lesions were completely responsive to dapsone therapy.

show abstract

Dapsone as a Glucocorticoid-Sparing Agent in Maintenance-Phase Pemphigus Vulgaris

Cited by 34 publications

References 26 publications

Efficacy of Dapsone in the Treatment of Pemphigus Vulgaris: A Single-Center Case Study

Efficacy of Dapsone in the Treatment of Pemphigus Vulgaris: A Single-Center Case Study

Minimizing Complications in Autoimmune Blistering Diseases

Pemphigus foliaceus induced by radiotherapy and responsive to dapsone

Contact Info

Product

Resources

About